【摘要】 目的分析孟鲁司特钠联合丹参酮治疗过敏性紫癜的临床疗效。方法选择在该院接受治疗的62例过敏性紫癜患儿作为研究对象,随机分为接受常规治疗的对照组及联合使用孟鲁司特钠及丹参酮治疗的观察组,比较治疗后两组患儿的炎症因子水平、T细胞亚群水平及不良反应等差异。结果观察组患者接受治疗后的IL-6、IgA和C3值明显低于对照组患者(P<0.05)。观察组患者接受治疗后的CD4+和CD4+/CD8+水平明显提升,CD8+水平下降(均P<0.05),CD3+水平则差异不具有显著性(P>0.05)。观察组与对照组患者的治疗后不良反应发生率差异不具有显著性(P>0.05)。结论孟鲁司特钠联合丹参酮有助于调节过敏性紫癜患儿的炎症因子水平,提高T细胞亚群功能状态,且安全性较好。更多还原

【Abstract】 【Objective】To analyze the efficacy of montelukast sodium combined tanshinone in children with anaphylactoid purpura. 【Methods】62 cases of patients with anaphylactoid purpura in our hospital were included in this study, randomly divided into control groups received normal treatment and observation group received montelukast sodium and tanshinone treatment, compared inflammatory cytokines, T cell subsets level and adverse reactions between the two groups.【Results】The levels of IL-6, IgA, C3 of patients in observation group after treatment were significantly lower than that in control group, but IL-21 levels were significantly higher(P <0.05). The levels of CD4+, CD4+/CD8+of patients in observation group were improved significantly, CD8+levels were decreased(P <0.05), CD3+level had no significant difference(P >0.05). Adverse reactions between two groups had no significant difference(P >0.05).【Conclusion】Montelukast sodium combined with tanshinone could optimize the levels of inflammatory factors in children with allergic purpura, and improve functional status of T cell subsets, and have satisfactory therapeutic safety.更多还原